Sugi Predict

Sugi Predict / Compounds / SCHEMBL5134084

SCHEMBL5134084

SCHEMBL5134084

CCOC(=O)[C@H](Cc1ccccc1)NS(=O)(=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.57

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 1/20 0.57
▸ CTSL P07711 2/20 0.55
▸ CTSS P25774 1/20 0.54
▸ MMP2 P08253 9/20 0.54
▸ MMP9 P14780 6/20 0.54
▸ ADAMTS4 O75173 1/20 0.54
▸ ALDH1A1 P00352 2/20 0.52
▸ MAPT P10636 1/20 0.52
▸ POLB P06746 1/20 0.52
▸ ITGA4 P13612 2/20 0.50
▸ ITGB7 P26010 2/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ ADAMTS5 Q9UNA0 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5041194 1.00 BACE1 (0.57) BACE1CTSLCTSSMMP2MMP9
SCHEMBL3839373 0.89 BACE1 (0.53) BACE1CTSLCTSSMMP2MMP9
SCHEMBL28243959 0.87 POLB (0.55) CTSLCTSSMMP2MMP9ADAMTS4
SCHEMBL26616349 0.86 MMP2 (0.73) MMP2MMP9ADAMTS4ALDH1A1MAPT
SCHEMBL26616346 0.86 MMP2 (0.73) MMP2MMP9ADAMTS4ALDH1A1MAPT
SCHEMBL5189459 0.86 MMP2 (0.73) MMP2MMP9ADAMTS4ALDH1A1MAPT
SCHEMBL8448000 0.83 MMP2 (0.59) CTSLCTSSMMP2MMP9ADAMTS4
SCHEMBL8593032 0.83 MMP2 (0.59) CTSLCTSSMMP2MMP9ADAMTS4
SCHEMBL3834652 0.83 HIF1A (0.52) BACE1CTSLCTSSMMP2MMP9
SCHEMBL9594962 0.82 MMP2 (0.50) BACE1MMP2MMP9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633354-B1 N-(((((1,3-THIAZOL-2-YL)AMINO)CARBONYL)PHENYL)SULFONYL)PHENYLALANINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF DIABETES INST FOR PHARM DISCOVERY INC (US) 2008-01-23 — — EP disclosed
CN-1794989-A N-(((((1,3-thiazol-2-yl)amino)carbonyl)phenyl)sulfonyl)phenylalanine derivatives and related compounds for the treatment of diabetes INST PHARMACEUTICAL DISCOVERY (US) 2006-06-28 — — CN disclosed
EP-1633354-A2 N-(((((1,3-THIAZOL-2-YL)AMINO)CARBONYL)PHENYL)SULFONYL)PHENYLALANINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF DIABETES The Institutes for Pharmaceutical Discovery, LLC (US) 2006-03-15 — — EP disclosed
US-20040248937-A1 Substituted phenylalkanoic acids for the treatment of diabetes THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC 2004-12-09 — — US disclosed
WO-2004092146-A2 N- (((((1,3-THIAZOL-2-YL) AMINO) CARBONYL) PHENYL) SULFONYL) PHENYLALANINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF DIABETES THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) 2004-10-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248937-A1 Substituted phenylalkanoic acids for the treatment of diabetes PTP4A1, PTPRJ, PPM1B BACE1 2058/4885CTSL 4443/4885CTSS 3952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.